|Ho: Ibalizumab for HIV Prevention
|Prophylactic neutralizing Ab
|Study Start Date:
|Study Made Public:
Assessment of ibalizumab neutralization potency and breadth
CAVD 309 is an immunogenicity study to assess the potency and breadth of the monoclonal antibody, Ibalizumab, against a diverse Env-pseudotype panel.
Sign in to see full information about this study and to download study data.
No non-integrated data is available for this study.